Pic: Luis Alvarez / DigitalVision via Getty Images
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
Health & Biotech
share
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.
Here’s a table showing how ASX-listed healthcare stocks have been performing.
| Code | Company | Price | % Six Month | % Month | % Week | Market Cap |
|---|---|---|---|---|---|---|
| TSN | The Sust Nutri Grp | 0.26 | -46 | -10 | 24 | $ 25,247,660.10 |
| RNO | Rhinomed Ltd | 0.25 | 52 | -19 | 11 | $ 63,452,283.00 |
| PIQ | Proteomics Int Lab | 1.05 | -7 | 21 | 11 | $ 105,655,875.00 |
| VHT | Volpara Health Tech | 1.1825 | -3 | -6 | 11 | $ 275,231,623.70 |
| PBP | Probiotec Limited | 2.22 | 13 | 3 | 10 | $ 161,634,616.36 |
| ADR | Adherium Ltd | 0.013 | -24 | 0 | 8 | $ 25,538,971.82 |
| TLX | Telix Pharmaceutical | 7.05 | 76 | 22 | 8 | $ 2,018,316,188.64 |
| IRX | Inhalerx Limited | 0.1 | 5 | -5 | 8 | $ 16,846,695.70 |
| 4DX | 4Dmedical Limited | 1.37 | 7 | 1 | 7 | $ 289,403,731.76 |
| RAP | Resapp Health Ltd | 0.059 | 5 | -9 | 5 | $ 49,833,430.47 |
| SDI | SDI Limited | 1.09 | 28 | 7 | 5 | $ 129,563,427.70 |
| RHT | Resonance Health | 0.11 | -42 | -4 | 5 | $ 50,693,717.91 |
| VBS | Vectus Biosystems | 1.45 | 49 | -24 | 5 | $ 48,170,224.52 |
| MEM | Memphasys Ltd | 0.1 | 79 | 56 | 4 | $ 72,880,407.00 |
| BIT | Biotron Limited | 0.05 | -2 | -2 | 4 | $ 35,096,635.65 |
| CYC | Cyclopharm Limited | 1.925 | -25 | -8 | 4 | $ 179,746,534.28 |
| EYE | Nova EYE Medical Ltd | 0.395 | 23 | -4 | 4 | $ 55,310,440.58 |
| ICR | Intelicare Holdings | 0.1 | -60 | 7 | 4 | $ 4,648,720.50 |
| BDX | Bcaldiagnostics | 0.15 | -3 | 3 | $ 19,728,984.30 | |
| IPD | Impedimed Limited | 0.18 | 44 | 6 | 3 | $ 310,767,187.85 |
| PSQ | Pacific Smiles Grp | 3.01 | 20 | 4 | 3 | $ 475,554,175.24 |
| ATX | Amplia Therapeutics | 0.19 | -17 | -2 | 3 | $ 29,469,197.79 |
| SOM | SomnoMed Limited | 2.37 | 7 | -2 | 3 | $ 195,311,983.40 |
| EZZ | EZZ Life Science | 0.49 | 0 | -3 | 2 | $ 5,880,000.00 |
| BWX | BWX Limited | 4.5 | -13 | -6 | 2 | $ 732,040,959.65 |
| HCT | Holista CollTech Ltd | 0.054 | 2 | -10 | 2 | $ 14,318,152.52 |
| PGC | Paragon Care Limited | 0.285 | 21 | -8 | 2 | $ 100,149,199.22 |
| MMJ | MMJ Group Hlds Ltd | 0.067 | -14 | -8 | 2 | $ 15,636,870.98 |
| ARX | Aroa Biosurgery | 1.15 | -1 | -2 | 1 | $ 391,432,924.32 |
| 1AD | Adalta Limited | 0.086 | -36 | 1 | 1 | $ 21,125,465.10 |
| ONT | 1300 Smiles Limited | 7.13001 | 16 | 0 | 1 | $ 168,827,114.70 |
| OVN | Oventus Medical Ltd | 0.099 | -18 | -16 | 1 | $ 23,930,926.97 |
| IHL | Incannex Healthcare | 0.565 | 109 | 59 | 1 | $ 682,818,321.70 |
| TRP | Tissue Repair | 0.62 | $ 27,741,395.18 | |||
| RAD | Radiopharm | 0 | $ - | |||
| SCU | Stemcell United Ltd | 0.014 | -26 | 0 | 0 | $ 14,606,489.21 |
| S66 | Star Combo | 0.28 | 10 | -5 | 0 | $ 37,719,491.32 |
| RSH | Respiri Limited | 0.059 | -41 | -12 | 0 | $ 42,647,606.61 |
| RGS | Regeneus Ltd | 0.071 | -27 | -3 | 0 | $ 21,757,020.89 |
| PYC | PYC Therapeutics | 0.145 | -3 | 0 | 0 | $ 493,043,545.97 |
| PAL | Palla Pharma Ltd | 0.395 | -1 | 16 | 0 | $ 63,955,699.39 |
| NEU | Neuren Pharmaceut. | 1.78 | 47 | -6 | 0 | $ 225,478,560.04 |
| MEB | Medibio Limited | 0.007 | 0 | -13 | 0 | $ 12,565,430.49 |
| ICS | ICSGlobal Limited | 0.575313 | -1 | 0 | 0 | $ 6,054,604.94 |
| FFC | Farmaforce Ltd | 0.055 | -31 | 8 | 0 | $ 7,187,453.90 |
| CMP | Compumedics Limited | 0.35 | -15 | -10 | 0 | $ 61,121,217.06 |
| BXN | Bioxyne Ltd | 0.022 | 5 | -19 | 0 | $ 15,363,489.55 |
| ALT | Analytica Limited | 0.002 | 0 | 0 | 0 | $ 9,227,602.26 |
| AHK | Ark Mines Limited | 0.034 | 0 | 0 | 0 | $ 1,778,919.95 |
| MVP | Medical Developments | 4.9 | -2 | 0 | 0 | $ 354,898,066.56 |
| NXS | Next Science Limited | 1.255 | -25 | 2 | 0 | $ 252,416,733.98 |
| UBI | Universal Biosensors | 0.91 | 32 | 21 | -1 | $ 158,199,144.72 |
| LDX | Lumos Diagnostics | 0.78 | -15 | -1 | $ 125,606,536.65 | |
| CYP | Cynata Therapeutics | 0.535 | -9 | -11 | -1 | $ 75,936,594.82 |
| LBT | LBT Innovations | 0.098 | 20 | -11 | -1 | $ 27,465,940.58 |
| GLH | Global Health Ltd | 0.41 | -44 | 14 | -1 | $ 23,209,850.72 |
| MDR | Medadvisor Limited | 0.39 | 30 | 5 | -1 | $ 145,332,608.96 |
| TRU | Truscreen | 0.075 | 4 | 0 | -1 | $ 27,214,968.98 |
| HXL | Hexima | 0.365 | 128 | -3 | -1 | $ 52,389,123.79 |
| CTE | Cryosite Limited | 0.355 | -1 | 4 | -1 | $ 17,327,394.87 |
| MVF | Monash IVF Group Ltd | 0.92 | 12 | -3 | -2 | $ 366,256,749.60 |
| CDY | Cellmid Limited | 0.061 | -5 | -8 | -2 | $ 13,433,264.15 |
| RCE | Recce Pharmaceutical | 0.855 | -18 | -8 | -2 | $ 148,588,609.19 |
| NYR | Nyrada Inc. | 0.235 | -20 | 0 | -2 | $ 28,882,169.05 |
| PCK | Painchek Ltd | 0.046 | -32 | -15 | -2 | $ 53,194,825.55 |
| OSX | Osteopore Limited | 0.225 | -55 | -17 | -2 | $ 26,385,353.55 |
| ADO | Anteotech Ltd | 0.205 | -41 | -18 | -2 | $ 414,102,508.26 |
| PAB | Patrys Limited | 0.039 | 45 | -2 | -3 | $ 74,269,178.84 |
| PAR | Paradigm Bio. | 2.16 | -11 | 14 | -3 | $ 493,087,209.93 |
| NSB | Neuroscientific | 0.36 | 18 | -13 | -3 | $ 52,367,149.70 |
| OCC | Orthocell Limited | 0.52 | 2 | -6 | -3 | $ 101,057,742.24 |
| 1ST | 1St Group Ltd | 0.0145 | -25 | -9 | -3 | $ 7,052,862.98 |
| CAN | Cann Group Ltd | 0.285 | -36 | -8 | -3 | $ 99,423,533.36 |
| AHC | Austco Healthcare | 0.14 | 43 | -3 | -3 | $ 39,786,453.14 |
| M7T | Mach7 Tech Limited | 0.9 | -15 | -9 | -4 | $ 224,235,317.25 |
| GSS | Genetic Signatures | 1.24 | 3 | -17 | -4 | $ 183,163,194.88 |
| TD1 | Tali Digital Limited | 0.024 | -35 | -14 | -4 | $ 23,297,644.73 |
| IMC | Immuron Limited | 0.12 | -27 | -4 | -4 | $ 27,309,551.52 |
| CAJ | Capitol Health | 0.355 | -1 | -4 | -4 | $ 383,319,079.44 |
| NOX | Noxopharm Limited | 0.465 | -17 | -13 | -4 | $ 140,274,216.00 |
| BNO | Bionomics Limited | 0.11 | -44 | -12 | -4 | $ 111,935,641.84 |
| CBL | Control Bionics | 0.43 | -28 | -26 | -4 | $ 20,384,016.93 |
| ZNO | Zoono Group Ltd | 0.405 | -42 | -14 | -5 | $ 66,951,646.34 |
| OIL | Optiscan Imaging | 0.2 | -51 | -7 | -5 | $ 123,637,120.40 |
| MX1 | Micro-X Limited | 0.3 | -6 | -6 | -5 | $ 128,835,768.60 |
| PNV | Polynovo Limited | 1.465 | -45 | -21 | -5 | $ 939,171,022.48 |
| OPT | Opthea Limited | 1.175 | -22 | -8 | -5 | $ 416,159,296.80 |
| BOT | Botanix Pharma Ltd | 0.059 | -21 | -5 | -6 | $ 56,442,240.29 |
| ALC | Alcidion Group Ltd | 0.335 | -6 | -3 | -6 | $ 351,103,132.42 |
| CGS | Cogstate Ltd | 2.26 | 181 | 1 | -6 | $ 400,435,860.48 |
| AVE | Avecho Biotech Ltd | 0.016 | -6 | -6 | -6 | $ 30,295,922.68 |
| RAC | Race Oncology Ltd | 3.29 | 0 | 3 | -6 | $ 563,783,828.14 |
| OSL | Oncosil Medical | 0.046 | -43 | -10 | -6 | $ 35,655,448.23 |
| VTI | Vision Tech Inc | 0.915 | -24 | -4 | -6 | $ 21,862,837.50 |
| MXC | Mgc Pharmaceuticals | 0.045 | -12 | -10 | -6 | $ 110,588,409.33 |
| PXS | Pharmaxis Ltd | 0.1075 | 34 | -2 | -7 | $ 56,434,058.56 |
| KZA | Kazia Therapeutics | 1.46 | 18 | -2 | -7 | $ 198,828,313.50 |
| ILA | Island Pharma | 0.27 | -23 | -14 | -7 | $ 11,675,654.82 |
| AT1 | Atomo Diagnostics | 0.195 | 11 | -46 | -7 | $ 75,607,712.35 |
| OSP | Osprey Med Inc | 0.75 | -56 | -18 | -7 | $ 19,243,906.50 |
| ZLD | Zelira Therapeutics | 0.037 | -20 | -12 | -8 | $ 47,220,570.75 |
| IDT | IDT Australia Ltd | 0.425 | 42 | -24 | -8 | $ 98,342,669.70 |
| DXB | Dimerix Ltd | 0.24 | -2 | -13 | -8 | $ 78,614,048.17 |
| CHM | Chimeric Therapeutic | 0.28 | -7 | -11 | -8 | $ 62,191,888.32 |
| NC6 | Nanollose Limited | 0.11 | 18 | 31 | -8 | $ 17,121,932.32 |
| MDC | Medlab Clinical Ltd | 0.165 | -15 | 3 | -8 | $ 56,458,985.72 |
| JTL | Jayex Technology Ltd | 0.022 | -39 | -12 | -8 | $ 5,483,027.86 |
| VLS | Vita Life Sciences.. | 1.72 | 64 | -4 | -9 | $ 90,562,492.64 |
| CDX | Cardiex Limited | 0.052 | -24 | -27 | -9 | $ 50,313,194.15 |
| ALA | Arovella Therapeutic | 0.041 | 17 | -15 | -9 | $ 19,717,756.08 |
| DVL | Dorsavi Ltd | 0.02 | -31 | 11 | -9 | $ 7,028,651.44 |
| ANP | Antisense Therapeut. | 0.2 | 3 | -35 | -9 | $ 134,850,983.38 |
| IMU | Imugene Limited | 0.5425 | 34 | 22 | -9 | $ 3,139,193,361.15 |
| NTI | Neurotech Intl | 0.065 | 12 | 30 | -10 | $ 46,713,413.44 |
| PTX | Prescient Ltd | 0.225 | 114 | -10 | -10 | $ 148,263,685.14 |
| EPN | Epsilon Healthcare | 0.099 | -38 | -36 | -10 | $ 20,234,229.65 |
| ATH | Alterity Therap Ltd | 0.026 | -4 | -13 | -10 | $ 62,578,739.03 |
| AGH | Althea Group | 0.255 | -33 | -15 | -11 | $ 79,669,910.87 |
| DOC | Doctor Care Anywhere | 0.5 | -40 | -30 | -11 | $ 95,103,218.50 |
| EXL | Elixinol Wellness | 0.089 | -41 | -11 | -11 | $ 29,063,828.19 |
| ACW | Actinogen Medical | 0.16 | 129 | 39 | -11 | $ 268,313,367.52 |
| PAA | Pharmaust Limited | 0.097 | 2 | 1 | -12 | $ 30,740,501.15 |
| RHY | Rhythm Biosciences | 1.7 | 60 | 25 | -12 | $ 362,399,015.06 |
| ACR | Acrux Limited | 0.11 | -24 | -8 | -12 | $ 28,368,033.80 |
| IMM | Immutep Ltd | 0.4975 | -18 | -18 | -13 | $ 435,475,128.51 |
| ONE | Oneview Healthcare | 0.265 | -13 | -34 | -13 | $ 135,739,897.20 |
| CU6 | Clarity Pharma | 0.9 | -20 | -13 | $ 153,042,712.43 | |
| BD1 | Bard1 Life Sciences | 1.055 | -56 | -2 | -14 | $ 96,531,666.00 |
| GTG | Genetic Technologies | 0.006 | -25 | -14 | -14 | $ 55,403,790.86 |
| AC8 | Auscann Grp Hlgs Ltd | 0.09 | -18 | -14 | -14 | $ 40,089,787.01 |
| BPH | BPH Energy Ltd | 0.041 | -54 | -33 | -15 | $ 27,261,694.95 |
| IBX | Imagion Biosys Ltd | 0.085 | -13 | 18 | -15 | $ 90,470,137.20 |
| AMT | Allegra Orthopaedics | 0.17 | -32 | -26 | -17 | $ 17,758,064.51 |
| LCT | Living Cell Tech. | 0.007 | -39 | -19 | -19 | $ 4,996,958.58 |
| CPH | Creso Pharma Ltd | 0.1 | -38 | -9 | -20 | $ 120,811,172.00 |
| IVX | Invion Ltd | 0.0185 | 106 | 42 | -26 | $ 115,384,745.32 |
| SHG | Singular Health | 0.215 | -26 | 0 | -28 | $ 15,202,968.27 |
The Sustainable Nutrition Group (ASX:TSN) was the biggest winner, up 24%.
The company recently announced it had partnered with Australian Plant Proteins to develop hemp concentrate and isolates, which would allow TSN to enter the $10.8 billion global plant-based ingredients market with limited capex requirements.
Commercialisation is expected to commence in Q4 FY2022 initially in the Australian and New Zealand markets.
Rhinomed (ASX:RNO) was up 11%, with chairman Ron Dewhurst telling shareholders at the AGM that the sales pipeline for the Rhinoswab looks strong into FY22.
“The product we have developed and have regulatory approval from the FDA in the US, and the TGA in Australia, has now been launched in the market and received initial orders from both the New South Wales and Victorian Government and further, has an identifiable pipeline of opportunities, both domestic and international,” he said.
“The early traction we have received makes us very optimistic about the relevance that the Rhinoswab will have for the company.”
Diagnostics tech company, Proteomics (ASX:PIQ) was up 11%.
The company signed off a two-year distribution deal with Apacor to bring its PromarkerD test for diabetic kidney disease to patients in England, Scotland and Wales.
And Volpara Health (ASX:VHT) was also up 11%.
The company’s FY22 half-year revenues increased significantly from NZ$19.9m in the prior corresponding period (pcp) to NZ$29 million.
Healthcare and life sciences expert Scott Power told Stockhead’s Eddy Sunarto that revenue guidance of NZ$25 million in FY 2022 is conservative.
Who flatlined?
Flat was PYC Therapeutics (ASX:PYC).
The company recently completed a key translational milestone for its RNA platform, by determining safe and well-tolerated doses of its co-lead drug candidate, VP-001, in monkeys.
The results are a key step towards toxicity studies scheduled for Q1 2022, that will then support the initiation of a first study in humans.
The human study is set to be the first therapy for patients with Retinitis Pigmentosa type 11 and will address the underlying cause of the disease.
Who’s the biggest loser?
The biggest loser was Singular Health (ASX:SHG) which dropped 28%.
The company has ventured out of medical markets by forming GeoVR Pty Ltd, a 50/50 joint venture (JV) with TerraCentric with the objective of commercialising the GeoVR technology.
GeoVR allows for mineral exploration and production data to be visualised in a fully interactive 3D environment.
Singular says the JV allows it to focus on the medical solutions sector, while branching out for diversified revenue sources.
And Invion (ASX:IVX) was down 26%.
The company has entered into conditional agreements with RMW Cho Group to co-develop Photosoft technology for cancer and related diseases (indications) with Invion to gain exclusive distribution rights to the tech in Asia Pacific for the indications.
Invion has also launched a $12 million placement and $3 million share purchase plan at $2.20 per share.
